– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with…
SINGAPORE, Dec. 17, 2024 /PRNewswire/ -- As Bitcoin surpassed the $100,000 mark on December 5, 2024, this landmark year for the…
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with…
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling…
December 09, 2024 12:00 ET | Source: Disc Medicine Inc Positive updates across all programs, including updates from ongoing clinical…
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – –…
“We had another outstanding quarter with record revenue and positive Adjusted EBITDA...We are very excited with our VSDHOne release and…
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each…
November 09, 2024 10:30 ET | Source: Ultragenyx Pharmaceutical Inc. Phase 1/2 data show improvements across all domains and confirm…